Le topiramate : un nouvel inducteur de granulome annulaire ?

Lagier, L.; Dunoyer, E.; Estève, É.

doi:10.1016/j.annder.2010.11.014

Cited by 5 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cases of association between the use of topiramate and the appearance of a GA‐like reaction have been reported in the literature only in recent years . Like these reports, the present case demonstrates the existence of a causal relationship between the occurrence of GA and topiramate.…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Granuloma annulare as a possible new adverse effect of topiramate

Cassone

Tumiati

2013

Int J Dermatology

View full text Add to dashboard Cite

Associations between the use of topiramate and a GA-like reaction have been reported in recent years. Based on the present case, it would appear that an actual association between GA and topiramate is possible given that: (i) the GA appeared only after the initiation of topiramate; (ii) the GA resolved after the discontinuation of topiramate; (iii) the GA reappeared with the resumption of topiramate in the same area and with the same characteristics as previously; and (iv) the lesion healed after topiramate was suspended.

show abstract

Section: Discussionsupporting

confidence: 77%

“…Our patient's past and recent medical history featured no other conditions associated with GA, but the literature includes only two similar cases that may confirm our proposition.…”

Section: Discussionsupporting

confidence: 74%

Granuloma annulare as a possible new adverse effect of topiramate

Cassone

Tumiati

2013

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Granuloma annulare has also been reported to develop at sites of resolved herpes zoster . In addition to these diseases, granuloma annulare induced by drugs such as allopurinol, pegylated IFN‐α, topiramate and TNF‐α inhibitors (infliximab, adalimumab and etanercept) has also been reported previously . Interestingly, it makes sense that IFN‐α, which activates macrophages, induces granulomatous inflammation, while a TNF‐α inhibitor can also induce granuloma annulare; this reaction was recently called a “paradoxical adverse reaction”.…”

Section: Granuloma Annularementioning

confidence: 63%

What is new in the histogenesis of granulomatous skin diseases?

Asai

2017

The Journal of Dermatology

View full text Add to dashboard Cite

A granuloma is a form of inflammation, which predominantly consists of macrophages. It typically develops when the immune system attempts to enclose substances that are usually insoluble and cannot be eliminated to prevent the spread of these substances to the other body compartments. According to the source of the substances, granulomatous diseases can be divided into two groups: infectious and non-infectious. The mechanisms of infectious granuloma formation have been widely investigated because of its easy reproducibility in experimental models, both in vivo and in vitro. On the contrary, mechanisms of non-infectious granuloma formation have not been well investigated because of the difficulty to reproduce this formation in experimental models. In this article, we review our recent understanding of the histogenesis and pathogenesis of granuloma formation, confirmed from studies of infectious granulomas, and we present potential hypotheses of the histogenesis and pathogenesis of non-infectious granulomas based on clinical investigations.

show abstract

“…Allopurinol, 21,80 paroxetine, 16 thalidomide, 81 pegylated IFN-a, 82,83 topiramate, 19,84 TNF-a inhibitors (infliximab, adalimumab, and etanercept), 22,23 and intranasal calcitonin 20 have all been reported to induce lesions clinically and histologically consistent with GA. As a result, for patients with new-onset GA, a detailed drug history should be performed. A trial off of the medication, if possible, can be performed to assess for resolution of cutaneous disease.…”

Section: Systemic Associationsmentioning

confidence: 97%

Granuloma Annulare

Keimig

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Granuloma annulare (GA) is a noninfectious granulomatous skin condition that can present with a variety of cutaneous morphologies. It is characterized by collagen degeneration, mucin deposition, and palisaded or interstitial histiocytes. Although the mechanism underlying development of GA is unknown, studies point to a cell-mediated hypersensitivity reaction to an as-yet undetermined antigen. Systemic associations with diabetes, thyroid disorders, lipid abnormalities, malignancy, and infection are described in atypical GA. Treatment is divided into localized skin-directed therapies and systemic immunomodulatory or immunosuppressive therapies. The selected treatment modality should be based on disease severity, comorbid conditions, consideration of potential side effects, and patient preference.

show abstract

Le topiramate : un nouvel inducteur de granulome annulaire ?

Cited by 5 publications

References 5 publications

Granuloma annulare as a possible new adverse effect of topiramate

Granuloma annulare as a possible new adverse effect of topiramate

What is new in the histogenesis of granulomatous skin diseases?

Granuloma Annulare

Contact Info

Product

Resources

About